The End of AbbVie’s $200 Billion Monopoly Won’t Sink the Stock

The drugmaker is heavily discounting its immune-disease drug Humira to protect market share this year.

WSJ News Exclusive | AbbVie Aims for New Drugs to Boost Sales as Competitors Target Humira

pharmaceutical company ABV Inc. is looking for its next hit. Now its blockbuster immune-disease therapy Humira…

Disney, Pepsi, Uber Set to Report During Lackluster Earnings Season

Business Income Fewer companies than usual are beating Wall Street estimates

Pfizer Expects Drop in Revenue as Covid Vaccine Demand Wanes

Business Health care Health Drugmaker says in earnings report it expects return to development of Covid-products…

U.S. Appeals Court Sides With Drugmakers on Discount Program

Business Health care Health Drug makers can limit shipments to hospitals and clinics of drugs subsidized…

Johnson & Johnson Fourth-Quarter Earnings Down 25%

The healthcare-products company reported a fourth-quarter sales decline as demand for its COVID-19 vaccine declined.

opinion | The West’s Drug-Price Self-Sabotage

A lesson from Europe to the US on how price controls reduce access to treatment and…

Moderna Finds Life After Covid-19

Market heard on the street Biotech Company Shows Its Vaccine Platform Will End the Pandemic

Moderna’s RSV Vaccine Reduces Risk of Respiratory Diseases, Study Finds

Health The company says the experimental shot was 83.7% effective against lower-respiratory diseases caused by RSV

Why Biotech Is Poised for a Recovery This Year

Market heard on the street Pharma and biotech stocks moved in opposite directions last year, but…